| Dr Rachel Marie Archer, MD | |
|
3800 S National Ave Ste 700, Springfield, MO 65807-5279 | |
| (417) 269-8817 | |
| (417) 269-8744 |
| Full Name | Dr Rachel Marie Archer |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 3800 S National Ave Ste 700, Springfield, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841558921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 2016019595 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocates For A Healthy Community Inc | 5395653562 | 34 |
News Archive
According to new developments patients with advanced Alzheimer's disease could benefit from drug treatment to slow its progression. Scientists have shown for the first time that drugs used to slow the disease in its early stages also work when the condition is advanced, greatly extending the population who could be treated.
University of Montreal researchers have discovered a novel molecular mechanism that can potentially slows the aging process and may prevent the progression of some cancers.
Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
Acura Pharmaceuticals, Inc. today announced clinical evaluation is now allowed under an Investigational New Drug application ("IND") filed with the U.S. Food and Drug Administration ("FDA") for a benzodiazepine product candidate utilizing our Aversion® Technology.
› Verified 9 days ago
| Entity Name | Advocates For A Healthy Community Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558303057 PECOS PAC ID: 5395653562 Enrollment ID: O20041109000631 |
News Archive
According to new developments patients with advanced Alzheimer's disease could benefit from drug treatment to slow its progression. Scientists have shown for the first time that drugs used to slow the disease in its early stages also work when the condition is advanced, greatly extending the population who could be treated.
University of Montreal researchers have discovered a novel molecular mechanism that can potentially slows the aging process and may prevent the progression of some cancers.
Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
Acura Pharmaceuticals, Inc. today announced clinical evaluation is now allowed under an Investigational New Drug application ("IND") filed with the U.S. Food and Drug Administration ("FDA") for a benzodiazepine product candidate utilizing our Aversion® Technology.
› Verified 9 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538334396 PECOS PAC ID: 1254248917 Enrollment ID: O20050624000293 |
News Archive
According to new developments patients with advanced Alzheimer's disease could benefit from drug treatment to slow its progression. Scientists have shown for the first time that drugs used to slow the disease in its early stages also work when the condition is advanced, greatly extending the population who could be treated.
University of Montreal researchers have discovered a novel molecular mechanism that can potentially slows the aging process and may prevent the progression of some cancers.
Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
Acura Pharmaceuticals, Inc. today announced clinical evaluation is now allowed under an Investigational New Drug application ("IND") filed with the U.S. Food and Drug Administration ("FDA") for a benzodiazepine product candidate utilizing our Aversion® Technology.
› Verified 9 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508928623 PECOS PAC ID: 5799787784 Enrollment ID: O20070213000001 |
News Archive
According to new developments patients with advanced Alzheimer's disease could benefit from drug treatment to slow its progression. Scientists have shown for the first time that drugs used to slow the disease in its early stages also work when the condition is advanced, greatly extending the population who could be treated.
University of Montreal researchers have discovered a novel molecular mechanism that can potentially slows the aging process and may prevent the progression of some cancers.
Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
Acura Pharmaceuticals, Inc. today announced clinical evaluation is now allowed under an Investigational New Drug application ("IND") filed with the U.S. Food and Drug Administration ("FDA") for a benzodiazepine product candidate utilizing our Aversion® Technology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rachel Marie Archer, MD Po Box 802843, Kansas City, MO 64180-2843 Ph: (417) 730-6430 | Dr Rachel Marie Archer, MD 3800 S National Ave Ste 700, Springfield, MO 65807-5279 Ph: (417) 269-8817 |
News Archive
According to new developments patients with advanced Alzheimer's disease could benefit from drug treatment to slow its progression. Scientists have shown for the first time that drugs used to slow the disease in its early stages also work when the condition is advanced, greatly extending the population who could be treated.
University of Montreal researchers have discovered a novel molecular mechanism that can potentially slows the aging process and may prevent the progression of some cancers.
Discovery Laboratories, Inc. announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.
Acura Pharmaceuticals, Inc. today announced clinical evaluation is now allowed under an Investigational New Drug application ("IND") filed with the U.S. Food and Drug Administration ("FDA") for a benzodiazepine product candidate utilizing our Aversion® Technology.
› Verified 9 days ago
Dr. Michael P. Smith-o'brien, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1900 S National Ave, Suite 2970, Springfield, MO 65804 Phone: 417-820-3980 Fax: 417-820-3988 | |
Roy Robert Reid Iii, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 5407 E Riverview St, Springfield, MO 65809 Phone: 417-827-3911 | |
Dr. Staci Dawn Rogers, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3800 S National Ave Ste 700, Springfield, MO 65807 Phone: 417-269-8817 Fax: 417-269-8744 | |
Dr. Megan Christine Rooney Thompson, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3850 S National Ave Ste 400, Springfield, MO 65807 Phone: 417-269-6850 Fax: 417-269-5830 | |
Dr. Laird A. Bell, M.D., MPH Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1423 N Jefferson Ave, #b100, Springfield, MO 65802 Phone: 417-269-8825 Fax: 417-269-8744 | |
Dr. Thomas M. Shultz, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1000 E Primrose St, Suite 270, Springfield, MO 65807 Phone: 417-882-6900 Fax: 417-882-8912 | |
Dr. Andy J. Wright, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2828 N National Ave, Springfield, MO 65803 Phone: 417-837-4000 Fax: 417-875-4710 |